Patents Examined by Raymond Henley, III
  • Dry powder inhaler
    Patent number: 9415008
    Abstract: This invention provides a dry powder inhaler comprising: a dry powder medicament comprising fluticasone propionate, salmeterol xinafoate and a lactose carrier; wherein, the delivered dose of fluticasone propionate per actuation is less than 100 ?g; and wherein the dose provides a baseline-adjusted FEV1 in a patient of more than 150 mL within 30 minutes of receiving the dose. A method of treating a patient includes administering to a patient a dry powder medicament having fluticasone propionate, salmeterol xinafoate and a lactose carrier; wherein, the delivered dose of fluticasone propionate per actuation is less than 100 ?g; and wherein the dose provides a baseline-adjusted FEV1 in a patient of more than 150 mL within 30 minutes of receiving the dose.
    Type: Grant
    Filed: January 20, 2016
    Date of Patent: August 16, 2016
    Assignee: Teva Branded Pharmaceutical Products R&D, Inc.
    Inventors: Mukul Dalvi, Seah Kee Tee
  • Iridium/rhodium anti-cancer compounds
    Patent number: 9408853
    Abstract: The present invention relates to novel iridium and/or rhodium containing complexes for use as a cytotoxic, such as an anti-cancer agent. There is also provided a method of preparing said compounds.
    Type: Grant
    Filed: May 20, 2011
    Date of Patent: August 9, 2016
    Assignee: University of Warwick
    Inventors: Abraha Habtemariam, Zhe Liu, Joan Josep Soldevila, Ana Maria Pizarro, Peter John Sadler
  • Human papilloma virus as predictor of cancer prognosis
    Patent number: 9410954
    Abstract: Methods of treating a head and neck cancer are disclosed.
    Type: Grant
    Filed: February 11, 2014
    Date of Patent: August 9, 2016
    Assignees: FOUNDATION MEDICINE, INC., UCL Business PLC
    Inventors: Chris Hendrik Boshoff, Timothy Robert Fenton, Matthias Alexander Lechner, Philip James Stephens, Matthew J. Hawryluk, Garrett Michael Frampton, Roman Yelensky
  • Broncholytic drug on the basis of prostaglandin
    Patent number: 9408820
    Abstract: The invention relates to the field of medicine, and specifically to pulmonology, and concerns a method for treating inflammatory and obstructive diseases of the airways, in particular bronchial asthma and obstructive bronchitis, with the aid of a drug on the basis of 1?,3?-dinitroglycerol ester 11(S),15(S)-dihydroxy-9-keto-5Z,13E-prostadienoic acid (nitroproston) having a marked bronchodilatory effect. The present invention provides for an expansion of the range of broncholytic drugs by the use of a derivative of natural prostaglandin E2, which is characterized by greater biological activity and the absence of noticeable side effects.
    Type: Grant
    Filed: March 1, 2013
    Date of Patent: August 9, 2016
    Assignee: OBSCHESTVO S OGRANICHENNOY OTVETSTVENNOST'YU “NOXI LAB”
    Inventors: Vladimir Vilenovich Bezuglov, Igor' Viktorovich Serkov
  • Pyruvate kinase activators for use in therapy
    Patent number: 9404081
    Abstract: Described herein are methods for using compounds that activate pyruvate kinase.
    Type: Grant
    Filed: May 3, 2012
    Date of Patent: August 2, 2016
    Assignee: AGIOS PHARMACEUTICALS, INC.
    Inventor: Shin-San Michael Su
  • Methods and compositions for treating leukemia
    Patent number: 9403747
    Abstract: The present invention provides methods and compositions for treating leukemia by cyclohexenone compounds.
    Type: Grant
    Filed: February 20, 2014
    Date of Patent: August 2, 2016
    Assignee: Golden Biotechnology Corporation
    Inventors: Sheng-Yung Liu, Wu-Che Wen, Chih-Ming Chen
  • Methods of using pyruvate kinase activators
    Patent number: 9403792
    Abstract: Described herein are compounds that activate pyruvate kinase, for use in a method for increasing lifetime of the red blood cells, for regulating 2,3-diphosphoglycerate levels in blood and for treating sickle cell anemia.
    Type: Grant
    Filed: May 3, 2012
    Date of Patent: August 2, 2016
    Assignee: AGIOS PHARMACEUTICALS, INC
    Inventor: Shin-San M. Su
  • Agents that prevent or repair skin damage
    Patent number: 9403778
    Abstract: The invention provides compounds of formula I: or a salt thereof as described herein. The invention also provides dermatological compositions comprising a compound of formula I or mixtures of one or more compounds of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I and therapeutic methods for protecting skin or DNA from photodamage or repairing photodamaged skin or DNA.
    Type: Grant
    Filed: January 11, 2013
    Date of Patent: August 2, 2016
    Assignee: Regents of the University of Minnesota
    Inventors: Robert Vince, Abbas Raza, Christine Dreis
  • Combined use of amides of mono- and dicarboxylic acids and silymarin in the treatment of renal diseases
    Patent number: 9399031
    Abstract: A therapy for renal diseases characterized by alterations of the kidney function, such as Chronic Kidney Disease (CKD), acute and chronic renal impairment, and renal diseases that develop in diabetic patients or in patients who underwent an anticancer chemotherapic treatment with a platinum derivative. The invention is a combination of compounds selected from mono- or diamide of a C12-C20 monocarboxylic acid, saturated or monounsaturated, or a C4-C14 dicarboxylic acid, saturated or monounsaturated, with an aminoalkanol, and compounds selected from Silymarin, derivatives thereof or conjugates or complexes thereof, for use in the treatment of renal diseases.
    Type: Grant
    Filed: July 3, 2014
    Date of Patent: July 26, 2016
    Assignee: Epitech Group S.r.l.
    Inventors: Francesco Della Valle, Maria Federica Della Valle, Gabriele Marcolongo, Salvatore Cuzzocrea
  • Gastroretentive tablets
    Patent number: 9393205
    Abstract: The present invention relates to a gastroretentive tablet comprising pregabalin, at least one swellable polymer, and other pharmaceutically acceptable excipients. It further relates to a process for the preparation of same.
    Type: Grant
    Filed: January 29, 2013
    Date of Patent: July 19, 2016
    Assignee: SUN PHARMACEUTICAL INDUSTRIES LIMITED
    Inventors: Varinder Kumar, Shavej Ahmad, Romi Barat Singh
  • Melanoma chemoprevention
    Patent number: 9393225
    Abstract: Disclosed herein are methods and uses for preventing melanoma, reducing progression of atypical nevi, and inducing cell cycle arrest and/or apoptosis in a melanoma cell through oral and enteral administration of sulforaphane to subjects indicated to be at risk due to factor(s) such as medical history of atypical nevi, melanoma, or UV exposure. Sulforaphane can be administered orally as a safe and well-tolerated natural agent as a chemopreventive strategy in individuals with atypical melanocytic nevi.
    Type: Grant
    Filed: May 3, 2013
    Date of Patent: July 19, 2016
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Jan H. Beumer, John M. Kirkwood, Shivendra V. Singh, Charles K. Brown
  • Methods and compositions employing bicifadine for treating disability or functional impairment associated with acute pain, chronic pain, or neuropathic disorders
    Patent number: 9393204
    Abstract: Methods and compositions are provided for formulating and administering bicifadine and related compounds to treat or prevent functional impairment and disabilities associated with acute pain, chronic pain, and neuropathic disorders.
    Type: Grant
    Filed: June 2, 2013
    Date of Patent: July 19, 2016
    Assignee: EBI Life Sciences, Inc.
    Inventors: Arnold S. Lippa, Warren Stern, Johnson Lim
  • Methods of using pyruvate kinase activators
    Patent number: 9388164
    Abstract: Described herein are methods for using compounds that activate pyruvate kinase.
    Type: Grant
    Filed: May 3, 2012
    Date of Patent: July 12, 2016
    Assignee: AGIOS PHARMACEUTICALS, INC
    Inventor: Shin-San M. Su
  • Pharmaceutical compositions containing phosphatidylserine and curcumin
    Patent number: 9381204
    Abstract: The present invention describes and claims stable pharmaceutical compositions and/or food supplements based on phosphatidylserine (PS) and curcumin, which are consequently devoid of degradation products, for use in the prevention and treatment of disorders associated with brain aging, and in the prevention and treatment of osteoporosis and/or osteoarthritis.
    Type: Grant
    Filed: January 23, 2013
    Date of Patent: July 5, 2016
    Assignee: FIDIA FARMACEUTICI S.P.A.
    Inventors: Giovanni Gennari, Susi Panfilo
  • Agricultural compositions comprising renewably-based biodegradable 1,3-propanediol
    Patent number: 9375390
    Abstract: Biodegradable agricultural compositions comprising 1,3-propanediol and its esters are provided. The 1,3-propanediol and its esters in the agricultural composition are biologically derived, and as such, the agricultural compositions exhibit a low anthropogenic CO2 emission profile.
    Type: Grant
    Filed: July 14, 2014
    Date of Patent: June 28, 2016
    Assignee: DuPont Tate & Lyle Bio Products Company, LLC
    Inventors: Robert Miller, Joseph Desalvo, Gyorgyi Fenyvesi, Raja Hari Poladi, Ann Wehner
  • Compositions, methods of treatment and diagnostics for treatment of hepatic steatosis alone or in combination with a hepatitis C virus infection
    Patent number: 9370528
    Abstract: The present invention is directed to pharmaceutical compositions and methods of treatment that relate to the inhibition, resolution and/or prevention of an array of the manifestations of metabolic syndromes, including Type 2 diabetes, hyperlipidemia, weight gain, obesity, insulin resistance, hypertension, atherosclerosis, fatty liver diseases and certain chronic inflammatory states that lead to these manifestations, among others. In additional aspects, the present invention relates to compositions and methods which may be used to treat, inhibit or reduce the likelihood of hepatitis viral infections, including Hepatitis B and Hepatitis C viral infections, as well as the secondary disease states and/or conditions which are often associated with such viral infections, including hepatic steatosis (steatohepatitis), cirrhosis, fatty liver and hepatocellular cancer, among other disease states or conditions.
    Type: Grant
    Filed: February 24, 2012
    Date of Patent: June 21, 2016
    Assignee: VOLANT HOLDINGS GMBH
    Inventors: Jerome Schentag, Joseph M. Fayad
  • Compositions of (-)-17-(cyclobutylmethyl)morphinan-3,14-diol
    Patent number: 9364430
    Abstract: The present invention is directed to oral, therapeutically effective modified release pharmaceutical compositions of (?)-17-(cyclobutylmethyl)morphinan-3,14-diol and it pharmaceutically acceptable salts and the use thereof, including delayed onset and extended release dosage forms. The present invention is also directed at modified release dosage forms of oral (?)-17-(cyclobutylmethyl)morphinan-3,14-diol which provide robust efficacy and reduced potential for abuse and misuse.
    Type: Grant
    Filed: October 31, 2011
    Date of Patent: June 14, 2016
    Assignee: Relmada Therapeutics, Inc.
    Inventor: Najib Babul
  • Treatment of cataplexy
    Patent number: 9359290
    Abstract: The present invention relates to a method of treating cataplexy in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of certain carbamate compounds.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: June 7, 2016
    Assignees: Jazz Pharmaceuticals International III Limited, SK Biopharmaceuticals Co., Ltd.
    Inventors: Moise A. Khayrallah, Gary Bream, Stephen E. Butts
  • Methods and compositions for treating trauma-hemorrhage using estrogen and derivatives thereof
    Patent number: 9359451
    Abstract: Disclosed are methods and materials for treating or preventing complications due to traumatic injuries using estrogen or derivatives thereof.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: June 7, 2016
    Assignee: THE UAB RESEARCH FOUNDATION
    Inventors: Irshad H. Chaudry, William J. Hubbard, Zheng Feng Ba
  • Therapeutic combinations of netupitant and palonosetron
    Patent number: 9358228
    Abstract: Combinations of netupitant and palonosetron, and methods of using such combinations to treat various pain states and irritable bowel syndrome, are provided.
    Type: Grant
    Filed: October 10, 2012
    Date of Patent: June 7, 2016
    Assignee: HELSINN HEALTHCARE SA
    Inventors: Claudio Pietra, Sergio Cantoreggi